Marker Therapeutics Shares Increase Over 15% Pre-Market: Why It Happened

By Amit Chowdhry ● Aug 20, 2021
  • The shares of Marker Therapeutics, Inc. (Nasdaq: MRKR) increased by over 15% pre-market. This is why it happened.

The shares of Marker Therapeutics, Inc. (Nasdaq: MRKR) – a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications – increased by over 15% pre-market. Investors are responding positively to the company announcing that they received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Company’s Phase 2 clinical trial of its lead MultiTAA-specific T cell product MT-401.

The CPRIT award is intended for supporting the adjuvant arm of the company’s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia (AML) following a hematopoietic stem cell transplant. And the primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group.

KEY QUOTE:

“We are honored to have been approved by CPRIT for this award which provides additional capital to support the clinical development of MT-401 and external validation of our technology from experts in the field who conducted business and scientific diligence on behalf of CPRIT. Our MultiTAA-specific T cell therapy approach has shown encouraging results in post-transplant AML in clinical studies, and we are pleased to advance the clinical development of MT-401 in our Phase 2 trial.”

– Peter L. Hoang, President & CEO of Marker Therapeutics

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.